Search
ETC-1001
go.drugbank.com/drugs/DB05866ExperimentalETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.
Etazolate
go.drugbank.com/drugs/DB05881InvestigationalEHT 0202 is developed to treat neurodegenerative disorders by ExonHit Therapeutics.
Synonyms: 1H-PYRAZOLO(3,4-B)PYRIDINE-5-CARBOXYLIC ACID, 1-ETHYL-4-((1-METHYLETHYLIDENE)HYDRAZINO)-, ETHYL ESTERGT 389-255
go.drugbank.com/drugs/DB05894ExperimentalPeptimmune’s lead product GT 389-255, is a novel lipase inhibitor and fat binding hydrogel polymer conjugate for the treatment of obesity which has completed single and multiple ascending dose (SAD and
rhIGFBP-3
go.drugbank.com/drugs/DB05897InvestigationalrhIGFBP-3 (recombinant human insulin-like growth factor binding protein-3) is Insmed’s proprietary anti-cancer compound that has demonstrated significant decreases in cancerous growth in several models of human. It is developed by Insmed...
Denibulin
go.drugbank.com/drugs/DB05932ExperimentalDenibulin is a novel small molecule Vascular Disrupting Agent under development by MediciNova for treatment of solid tumor cancers.
PRTX-100
go.drugbank.com/drugs/DB05947InvestigationalPRTX-100 is a highly-purified form of Staphylococcal Protein A that binds directly to monocytes and a subset of B-cells that are involved in the development and progression of various autoimmune diseases
Synonyms: Staphylococcus aureus protein AEGEN-001
go.drugbank.com/drugs/DB05953InvestigationalEGEN-001 is a novel non-viral vector consisting of a plasmid DNA encoding the human gene for interleukin 12 (IL-12) and a biocompatible, biodegradable delivery polymer with potential antineoplastic activity